New York jury finds that Teva and distributor Anda violated state’s public nuisance law in their marketing and distribution of opioids. Such claims had been rejected by two previous courts and the verdict in this case shows the challenges companies face in ongoing litigation.

Show depicts former agency officials approving OxyContin labeling that enabled Purdue to market it as nonaddictive and subsequently refusing pleas to restrict its use.

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.